Ferah Taran

Ferah Taran

Auto-generated profile, based on publicly available information

Ferah Taran

Ondokuz Mayis University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2026 in Medicine
Verified
Journal Article
Open access
FTFerah Taran
Ferah Taran
ETErcan Türkmen
Ercan Türkmen
Tacrolimus is a key immunosuppressant with a narrow therapeutic range in kidney transplantation. Early fluctuations in trough concentrations may influence graft stability, yet the clinical significance of early intrapatient variability remains uncertain. This study aimed to evaluate whether tacrolimus variability during the first posttransplant month is associated with renal function at 12 months. This single-center retrospective cohort study included adult kidney transplant recipients receiving tacrolimus-based immunosuppression between January 2017 and December 2021. Tacrolimus variability was quantified as the absolute difference (Δ, ng/mL) between maximum and minimum trough concentrations during the first 30 days, classified as high (Δ > 8 ng/mL) or low (Δ ≤ 8 ng/mL). Renal function was assessed using eGFR at 1, 3, 6, and 12 months. Statistical analyses applied appropriate parametric and nonparametric tests with a significance level of P < .05. High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance. However, 12-month eGFR was not significantly different between variability groups. In multivariable models, recipient age, donor age, and biopsy-proven graft dysfunction were consistently associated with lower eGFR across follow-up. Male donor sex showed a positive association with eGFR only at 6 months, whereas early tacrolimus variability was not independently associated with eGFR at any time point.

8 May 2026 in Medicine
Verified
Journal Article
Open access
FTFerah Taran
Ferah Taran
HSHayriye Sayarlioglu
Hayriye Sayarlioglu
Dialysate sodium concentration (dNa) is a key determinant of hemodynamic stability during hemodialysis. However, the clinical relevance of small reductions in dNa remains uncertain, particularly regarding intradialytic blood pressure variability and ultrafiltration efficiency. This study aimed to evaluate the effect of reducing dialysate sodium from 140 mmol/L to 138 mmol/L on intradialytic systolic and diastolic blood pressure variability, interdialytic weight change, and ultrafiltration adequacy. This prospective, single-center cross-over study included ten adult hemodialysis patients (N = 10) treated sequentially with dNa concentrations of 140 and 138 mmol/L for 2 consecutive months (12 sessions per phase). Paired comparisons were performed using Wilcoxon signed-rank tests. No significant differences were observed between 140 mmol/L and 138 mmol/L dialysate sodium in systolic or diastolic BP variability, interdialytic weight gain, intradialytic weight loss, or ultrafiltration adequacy (all P > .05). Median systolic BP variability was 15.9 mm Hg (IQR 13.0–18.2) vs 14.3 mm Hg (IQR 12.4–18.4) (HL diff 2.00 [95 % CI–7.44, 6.53]); diastolic BP variability 7.9 mm Hg (IQR 6.8–11.0) vs 7.9 mm Hg (IQR 7.7–8.8) (HL diff–0.15 [95 % CI–3.90, 3.35]). Exploratory subgroup trends (greater systolic variability in females, lower in CAD patients under 138 mmol/L) were not statistically reliable due to small group sizes. A modest 2 mmol/L reduction in dialysate sodium was not associated with clear short-term changes in hemodynamic or fluid-related effects. Larger multicenter studies are needed to clarify the clinical impact of individualized sodium prescriptions.

26 September 2022 in Journal of Medicine and Palliative Care
Verified
Journal Article
Closed access
PDF file
AGArif Cengiz Gülteki̇n
Arif Cengiz Gülteki̇n
ETErcan Türkmen
Ercan Türkmen
FTFerah Taran
Ferah Taran
MDMelda Di̇lek
Melda Di̇lek
HSHayriye Sayarli̇oglu
Hayriye Sayarli̇oglu
NANurol Arik
Nurol Arik
Aim: Renal replacement therapies (RRT), including dialysis modalities and renal transplantation (RT), affect patients’ quality of life (QoL) differently. This study aimed to determine the factors affecting the QoL in hemodialysis (HD) and RT patients. Material and Method: One hundred patients in each RT and HD group were included in the study. Socio-demographic data was determined with a questionnaire. Laboratory information and other medical information of the patients were obtained from the medical records. Short Form-36 (SF-36) and Nottingham Health Profile (NHP) scales were used to assess the QoL. Results: The mean ages in HD and RT patients were 58.28±15.21 and 47.92±12.01 years. Most patients were male (53% HD, 68% RT). RT patients had a higher QoL than HD patients in all components. On the NHP scale, RT patients had higher QoL in all parts except social isolation and emotional reactions. Male gender, non-smoker status, high education level, being employed and living in the city, and some laboratory parameters (hemoglobin, ferritin, sodium, calcium, magnesium, and albumin) positively affected the QoL in the HD group; diabetes and CVD had a negative impact on the QoL. In the RT group, male gender, high education level, being employed; normal potassium, phosphorus, and parathormone levels affect QoL positively while hypertension and CVD negatively affect the QoL. Conclusion: Factors affecting QoL in patients receiving RRT are different. Efforts to correct laboratory parameters may impact the quality of life in HD patients. Returning to working life could increase the QoL in RT patients.

30 May 2022 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ETErcan Türkmen
Ercan Türkmen
MAMahmut Altindal
Mahmut Altindal
FTFerah Taran
Ferah Taran
TKTuba Kuruoğlu
Tuba Kuruoğlu
ADAydın Deveci
Aydın Deveci
NKNurhan Köksal
Nurhan Köksal
Introduction/Aim: Hyponatremia (serum sodium 0.001) were the independent predictors of hyponatremia at the time of admission. The median length of hospital stay (LOS) was longer in patients with hyponatremia than patients with normonatremia (10 days vs. 8 days, p < 0.001). In multivariate analysis, hyponatremia was significantly associated with ICU admission or the need for mechanical ventilation (adjusted OR, 1.72; 95% confidence interval [95% CI], 1.03 to 2.85; p = 0.036). The severity of pneumonia, hemoglobin and lactate dehydrogenase levels, neutrophil-to-lymphocyte ratio (NLR), and body temperature were also associated with ICU admission or the need for mechanical ventilation. The oxygen saturation, male sex, serum albumin, NLR, and the ICU admission but not the hyponatremia on admission were significantly related to mortality. Conclusion: Hyponatremia on admission, even when mild, predicts a worse outcome in COVID-19 patients, and it should be considered in risk stratification.